Noruxol Ointment 10g,Noruxol Unguento 10g,SMITH & NEPHEW LTD

“ACTIVE substances: 1 g of ointment contains 0.52/3.75 mg of collagenase N, contains at least 1.2 Units of clostridiopeptidase B and at least 0.24 Units of protease bound. Excipients: liquid paraffin, white petroleum jelly.
INDICATIONS: Enzyme purification from necrotic ulcers including leg ulcers and bedsore ulcers.
CONTRAINDICATIONS/EFF.SECONDARY: Hypersensitivity to the active substance (collagenase) or to any of the excipients of the ointment.
DOSAGE: To ensure successful treatment of cu tanee enzymatic injuries, there must be sufficient moisture in the l hesion area. Thus, in dry wounds, the base of the bruise should be their king, moistened with saline (0.9% NaCl) or other solutions that are well tolerated by the tissue (eg glucose). Dry crusts and two kings should be, first softened, apply a damp bandage. A layer of ointment about 2 mm thick should be applied to the dressing table or directly to the area, slightly moistened, once a day. Cover the surface of the injury to ensure contact. There is no need to apply a generous layer of pro duct to the bruise, as this does not contribute to the progress of d etersione. As a rule, it is enough to change the dressing once a day, unless medical advice is otherwise.
STORAGE CONDITIONS: Store at temperatures below 25 degrees C.
Special INSTRUCTIONS: Repeated use of topical products may result in sensitization. Whenever an infection is present, appropriate antibiotic treatment should be considered. Cloramfenic oils, neomycin, framicetina, bacitracin, gentamicin, polymyxin, and macrolides (eg, erythromycin) are shown to be compatible with l-collagenase. Contact with eyes and mucous membranes should be avoided. In patients with severe burns, use should occur on ind, ic and under the supervision of a specialist. In diabetic patients, l and gangrene, dry ones should be moistened, taking precautions to avoid transformation into wet gangrene. If r iduzione component of necrosis is not observed within 14 days from the start of therapy with the drug, it is recommended to stop treatment and take alternative methods of surgical debridement. After initial opening the product can no longer be considered sterile. Any sidu king thus cannot be used but must be excluded.
INTERACTIONS: The drug should not be used in the presence of antiseptics, detergents and soaps, as they inhibit enzyme activity. Products based on silver and silver sulfadiazine, I can not, however, be used together with the medicine without changing the att ive’ enzyme. Tirotricina, gramicidina and tetracyclines were not to be used topically with the product.
SIDE EFFECTS: Side effects may include local pain, itching, bruises and erythema. In case of severe reactions, cessation of therapy should be taken into account.
PREGNANCY AND BREAST-FEEDING: Although no teratogenic effects have been identified, the product should be administered during the first three months of pregnancy only or strictly as indicated. Since collagenase is not included in the cir breakfast systemically and it is far-fetched that it is excreted in breast milk. 028039016″